Your session is about to expire
← Back to Search
Noninvasive Cardiac Radioablation for Rapid Heartbeat (ENCORE-VT Trial)
ENCORE-VT Trial Summary
This trial is testing a new, minimally invasive treatment for ventricular tachycardia that doesn't require surgery.
ENCORE-VT Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowENCORE-VT Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.ENCORE-VT Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You must be older than 18 years.The doctors think you may not live for another year, even with the best care.You have severe heart failure symptoms and need specific heart treatments.You have certain irregular heart rhythms called polymorphic ventricular tachycardia or ventricular fibrillation.You have a heart condition that makes it unsafe for the doctor to use a certain type of treatment.You have tried at least one antiarrhythmic medication (like amiodarone, sotalol, or mexiletine) and it didn't work for you or caused you problems.You have experienced more than 3 different types of rapid heartbeats, or more than 5 different types of rapid heartbeats induced during a specific heart test.You have been diagnosed with sustained monomorphic ventricular tachycardia or monomorphic premature ventricular contractions (PVCs) based on specific heart tests.You have already tried a certain type of heart procedure without success, or you cannot have this procedure, or your heart condition is in a difficult-to-reach area.You have had at least 3 episodes of ventricular tachycardia (VT) or a high burden of premature ventricular contractions (PVC) with a weakened heart.
- Group 1: stereotactic body radiotherapy (SBRT)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Can people with the qualifying condition still enroll in this experiment?
"This study, as it is noted on clinicaltrials.gov, is not currently seeking new participants. The trial was originally posted on 7/1/2016 and updated lastly on 12/1/2021. There are 299 other trials that are recruiting patients right now if you're interested in participating in a clinical trial."
What are researchers looking to discover through this experiment?
"This clinical trial's primary goal is to assess the reduction in ventricular tachycardia (VT) burden over a period of approximately 90 days. Secondary outcomes include measuring the number of participants who experience a reduction in VT therapies between 6 and 12 months, as well as those with reduced ICD shocks or improved left ventricular ejection fraction (LVEF). For patients with PVC-induced cardiomyopathy, another secondary outcome measures longer-term durability by evaluating the persistence of any reduction in PVC burden based on ambulatory heart monitors during early and late phases of the study."
Share this study with friends
Copy Link
Messenger